PE20071168A1 - Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip - Google Patents

Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip

Info

Publication number
PE20071168A1
PE20071168A1 PE2006001653A PE2006001653A PE20071168A1 PE 20071168 A1 PE20071168 A1 PE 20071168A1 PE 2006001653 A PE2006001653 A PE 2006001653A PE 2006001653 A PE2006001653 A PE 2006001653A PE 20071168 A1 PE20071168 A1 PE 20071168A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidin
diphenylfide
pyrimidine
receptor
Prior art date
Application number
PE2006001653A
Other languages
English (en)
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Barfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20071168A1 publication Critical patent/PE20071168A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES O, S, NR5; R5 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, CICLOALQUENILO C4-C7; L ES ALCANO C1-C7 DIILO, SUSTITUIDO O NO; Z ES A, B, ENTRE OTROS; R7 ES H, ALQUILO C1-C4; R1 Y R2 SON CADA UNO HALOGENO, CIANO, NITRO, ALQUILO C1-C6, CICLOALQUILO C3-C7, TRIFLUOROMETOXI, ENTRE OTROS; n Y o SON 0-3; R3 ES H, ALQUILO C1-C4; R4 ES H, CICLOPROPILO, ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: ACIDO 6-{[5-(4-METOXIFENIL)-6-FENILFURO[2,3-d]PIRIMIDIN-4-IL]AMINO}HEXANOICO; ACIDO 7-{[5-(4-METOXIFENIL)6-FENILFURO[2,3-d]PIRIMIDIN-4-IL]AMINO}HEPTANOICO; 5-(4-METOXIFENIL)-6-FENIL-N-{3-[2-(1H-TETRAZOL-5-IL)ETOXI]PROPIL}FURO[2,3-d]PIRIMIDIN-4-AMINA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES
PE2006001653A 2005-12-21 2006-12-20 Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip PE20071168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005061170A DE102005061170A1 (de) 2005-12-21 2005-12-21 Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20071168A1 true PE20071168A1 (es) 2008-02-07

Family

ID=37876878

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001653A PE20071168A1 (es) 2005-12-21 2006-12-20 Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip

Country Status (32)

Country Link
US (1) US8183246B2 (es)
EP (1) EP1966217B1 (es)
JP (1) JP5254032B2 (es)
KR (1) KR101429777B1 (es)
CN (1) CN101384603B (es)
AR (1) AR058108A1 (es)
AU (1) AU2006334856B2 (es)
BR (1) BRPI0620317A2 (es)
CA (1) CA2633701C (es)
CR (1) CR10092A (es)
DE (1) DE102005061170A1 (es)
DK (1) DK1966217T3 (es)
DO (1) DOP2006000280A (es)
EC (1) ECSP088569A (es)
ES (1) ES2418855T3 (es)
GT (1) GT200800117A (es)
HK (1) HK1130054A1 (es)
IL (1) IL192062A0 (es)
MA (1) MA30039B1 (es)
NO (1) NO20082986L (es)
NZ (1) NZ569214A (es)
PE (1) PE20071168A1 (es)
PL (1) PL1966217T3 (es)
PT (1) PT1966217E (es)
RU (1) RU2454419C2 (es)
SV (1) SV2009002953A (es)
TN (1) TNSN08279A1 (es)
TW (1) TWI405764B (es)
UA (1) UA94080C2 (es)
UY (1) UY30046A1 (es)
WO (1) WO2007079862A1 (es)
ZA (1) ZA200805385B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019691A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
WO2013168760A1 (ja) 2012-05-10 2013-11-14 武田薬品工業株式会社 芳香環化合物
JPWO2013168759A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
AU2020274083A1 (en) * 2019-05-13 2021-11-18 D.E. Shaw Research, Llc FGFR inhibitors and methods of use thereof
KR102094337B1 (ko) 2019-10-01 2020-03-27 안문호 금속이물질 제거장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
EP1018514B1 (en) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
HUP0104841A3 (en) 1999-09-17 2002-07-29 Daiichi Suntory Pharma Co Ltd Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency
ATE319718T1 (de) 2001-05-14 2006-03-15 Novartis Pharma Gmbh Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20030225098A1 (en) * 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR20050091462A (ko) * 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
MXPA06014256A (es) 2004-06-10 2007-03-12 Xention Discovery Ltd Compuestos de furano-pirimidina efectivos como inhibidores del canal de potasio.
US7776867B2 (en) * 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines

Also Published As

Publication number Publication date
TWI405764B (zh) 2013-08-21
CN101384603A (zh) 2009-03-11
KR101429777B1 (ko) 2014-08-19
GT200800117A (es) 2009-12-16
SV2009002953A (es) 2009-04-28
EP1966217B1 (de) 2013-05-08
EP1966217A1 (de) 2008-09-10
US20090318475A1 (en) 2009-12-24
DE102005061170A1 (de) 2007-07-05
PT1966217E (pt) 2013-07-12
MA30039B1 (fr) 2008-12-01
CA2633701A1 (en) 2007-07-19
UY30046A1 (es) 2007-07-31
WO2007079862A1 (de) 2007-07-19
DK1966217T3 (da) 2013-08-05
DOP2006000280A (es) 2007-07-31
ECSP088569A (es) 2008-08-29
JP2009520713A (ja) 2009-05-28
TNSN08279A1 (en) 2009-10-30
JP5254032B2 (ja) 2013-08-07
KR20080081323A (ko) 2008-09-09
AU2006334856A1 (en) 2007-07-19
BRPI0620317A2 (pt) 2011-11-08
IL192062A0 (en) 2008-12-29
CN101384603B (zh) 2012-08-01
TW200745132A (en) 2007-12-16
RU2008129363A (ru) 2010-01-27
NZ569214A (en) 2011-07-29
PL1966217T3 (pl) 2013-09-30
ES2418855T3 (es) 2013-08-16
HK1130054A1 (en) 2009-12-18
ZA200805385B (en) 2009-10-28
NO20082986L (no) 2008-07-02
AR058108A1 (es) 2008-01-23
CA2633701C (en) 2014-05-27
CR10092A (es) 2008-10-08
US8183246B2 (en) 2012-05-22
AU2006334856B2 (en) 2013-04-04
UA94080C2 (ru) 2011-04-11
RU2454419C2 (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
PE20071168A1 (es) Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip
PE20051141A1 (es) Inhibidores de la polimerasa viral
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
CA2900308C (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20121440A1 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20060623A1 (es) Compuestos de sulfonamida como potenciadores del receptor de glutamato
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20081467A1 (es) Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk)
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20051047A1 (es) COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed